[go: up one dir, main page]

WO2024238598A3 - Stat degraders and uses thereof - Google Patents

Stat degraders and uses thereof Download PDF

Info

Publication number
WO2024238598A3
WO2024238598A3 PCT/US2024/029364 US2024029364W WO2024238598A3 WO 2024238598 A3 WO2024238598 A3 WO 2024238598A3 US 2024029364 W US2024029364 W US 2024029364W WO 2024238598 A3 WO2024238598 A3 WO 2024238598A3
Authority
WO
WIPO (PCT)
Prior art keywords
degraders
stat
stat6
satis
stat3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/029364
Other languages
French (fr)
Other versions
WO2024238598A2 (en
Inventor
Neil Bifulco
Howard Bregman
Giovanni Cianchetta
Brian Hodous
Samuel K. REZNIK
Yong Tang
Andrew Tasker
Rishi G. Vaswani
Ernest Allen SICKMIER
John Yeoman
Xia TIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recludix Pharma Inc
Original Assignee
Recludix Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recludix Pharma Inc filed Critical Recludix Pharma Inc
Publication of WO2024238598A2 publication Critical patent/WO2024238598A2/en
Publication of WO2024238598A3 publication Critical patent/WO2024238598A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are compounds of Formula (I): and pharmaceutically acceptable satis and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.
PCT/US2024/029364 2023-05-15 2024-05-15 Stat degraders and uses thereof Pending WO2024238598A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363466563P 2023-05-15 2023-05-15
US63/466,563 2023-05-15

Publications (2)

Publication Number Publication Date
WO2024238598A2 WO2024238598A2 (en) 2024-11-21
WO2024238598A3 true WO2024238598A3 (en) 2025-05-30

Family

ID=93520240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/029364 Pending WO2024238598A2 (en) 2023-05-15 2024-05-15 Stat degraders and uses thereof

Country Status (1)

Country Link
WO (1) WO2024238598A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025218706A1 (en) * 2024-04-16 2025-10-23 先声药业有限公司 Stat6-selective degrader compound and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200121693A1 (en) * 2014-06-04 2020-04-23 Sanford Burnham Prebys Medical Discovery Institute Use of Inhibitor of Apoptosis Protein (IAP) Antagonists in HIV Therapy
WO2020206424A1 (en) * 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200121693A1 (en) * 2014-06-04 2020-04-23 Sanford Burnham Prebys Medical Discovery Institute Use of Inhibitor of Apoptosis Protein (IAP) Antagonists in HIV Therapy
WO2020206424A1 (en) * 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAI ET AL.: "A Potent and Selective Small-molecule Degrader of STAT3 Achieves Complete Tumor Regression in vivo", CANCER CELL, vol. 36, no. 5, 2019, pages 498 - 511, XP085906227, DOI: 10.1016/j.ccell.2019.10.002 *
CAL ET AL.: "A potent and orally active antagonist of multiple inhibitor of apoptosis proteins (lAPs) (SM-406/ AT -406) in clinical development for cancer treatment", J MED CHEM., vol. 54, no. 8, 28 April 2011 (2011-04-28), pages 2714 - 2726, XP055084190, DOI: 10.1021/jm101505d *

Also Published As

Publication number Publication date
WO2024238598A2 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
CA3247154A1 (en) Stat modulators and uses thereof
CA3252262A1 (en) Stat modulators and uses thereof
MY161369A (en) Novel tricyclic compounds
BRPI0413469A (en) piperazine derivatives for the treatment of hiv infections
WO2004004657A3 (en) Hiv integrase inhibitors
NO20076137L (en) New 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidemia
TW200602036A (en) Diphenylazetidone derivates
NO20076138L (en) New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidemic conditions
EA017861B9 (en) Method for producing 4-oxoquinoline compound
WO2024238598A3 (en) Stat degraders and uses thereof
WO2022104153A3 (en) Compounds and methods for treating viral infections
MX2022008487A (en) Smarca2-vhl degraders.
WO2023178065A3 (en) Lipid compounds and lipid nanoparticles
EP4480483A3 (en) Solid state forms of belumosudil and belumosudil salts
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
NO20071321L (en) Anti-inflammatory drugs
MX2025001749A (en) Compound as voltage-gated sodium channel inhibitor
MX2025012370A (en) Amide compound, pharmaceutical composition comprising same, and use thereof
WO2024249888A3 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
WO2007004072A3 (en) Formulations and methods for treating amyloidosis
CR20250103A (en) Modulators of alpha-1 antitrypsin
CA3244694A1 (en) Solid state forms of gusacitinib
WO2024238603A3 (en) Stat degraders and uses thereof
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
CR20230542A (en) Modulators of trex1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24807965

Country of ref document: EP

Kind code of ref document: A2